An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
https://doi.org/10.24411/2588-0519-2018-10056
Abstract
Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim. To update pharmacoeconomic evaluation of T-DM1 in patients with HER2+ breast cancer (BC) and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis were performed. Direct medical costs and indirect costs (GDP loss) were accounted. Results. At 5 years modeling horizon total cost of trastuzumab emtanzine were higher comparing to lapatinib+capecitabine due to significantly higher overall survival (OS) observed in T-DM1 group. CER OS for T-DM1 was by 21% lower comparing to CER lapatinib+capecitabine (2 099 940 RUR/patient/year and 2 541 879 RUR/patient/year, consequently). Conclusions. The study showed T-DM1 is a cost-effective strategy in patient with HER2+ metastatic BC and CNS metastases.
About the Authors
A. S. Kolbin
I.P. Pavlov First SPbSMU MOH Russia; St. Petersburg State University
Russian Federation
Russian Federation
Kolbin Alexey - MD, Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg; professor of the Department of Pharmacology, Medical Faculty, St. Petersburg State University.
SPIN-code: 7966-0845
A. A. Kurylev
St. Petersburg State University
Russian Federation
Russian Federation
Kurylev Alexey - Candidate of Physico-mathematical sciences, Department of control processes, faculty of applied mathematics.
Y. E. Balykina
St. Petersburg State University
Russian Federation
Russian Federation
Balykina Julia - Candidate of Physico-mathematical sciences, Department of control processes, faculty of applied mathematics.
M. A. Proskurin
St. Petersburg State University
Russian Federation
Russian Federation
Proskurin Maksim - assistant of the Department of mathematical modeling of energy systems, faculty of applied mathematics and control processes.
SPIN-code: 7406-2352
References
1. Onkologiya: uchebnik s kompakt-diskom / pod red. VI CHissova, SL Dar’yalo-voj. Moscow: GEHOTAR-Media, 2007 (In Russ).
2. Pod red. AD Kaprina, VV Starinskogo, GV Petrovoj. Sostoyanie onkologi-cheskoj pomoshchi naseleniyu Rossii v 2017 godu. Moscow: MNIOI im. P.A. Gercena filial FGBU «NMIC radiologii» Minzdrava Rossii, 2018. (In Russ).
3. Mueller V, et al. Brain metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients treated with brain metastases from breast cancer. JCO 2016; 34 (suppl. Abstr 2070)
4. Associaciya onkologov Rossii. Klinicheskie rekomendacii po diagnostike i lecheniyu bol’nyh rakom molochnoj zhelezy. (In Russ). Электронный ресурс: URL: http://oncology-association.ru/docs/recomend/may2015/24vz-rek.pdf
5. Stenina MB, Vladimirova LYu, Gladkov OA, et al. Prakticheskie reko-mendacii po lekarstvennomu lecheniyu raka molochnoj zhelezy. Zlokachestvennye opuholi. 2015;4, specvypusk:99—115 (In Russ).
6. NCCN Clinical practice guidelines in oncology. Breast cancer. Version 2.2017 — April 26, 2017. Электронный ресурс. URL: www.nccn.org.
7. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014;23(5):489—502.
8. Kulikov AYu, Komarov IA. Farmakoehkonomicheskij analiz lekarstvennogo sredstva kadsila (trastuzumab ehmtanzin) v lechenii raka molochnoj zhelezy u bol’nyh s HER2+ formoj zabolevaniya. Farmakoehkonomika: teoriya i praktika. 2015;3(2):24—31. (In Russ).
9. Kulikov AYu, Komarov IA. Farmakoehkonomicheskij analiz lekarstvennogo sredstva kadsila (trastuzumab ehmtanzin) v lechenii raka molochnoj zhelezy u bol’nyh s HER2+ formoj zabolevaniya. Farmakoehkonomika: teoriya i praktika. 2015;3(2):24—31 (In Russ).
10. Kolbin AS, Kurylev AA, Balykina YE, et al. Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in patients with HER2+ breast cancer and central nervous system metastases. Kachestvennaya klinicheskaya praktika. 2017;2:4—11. (In Russ).
11. Nacional’nyj standart Rossijskoj Federacii. GOST R 56044- 2014. Ocenka medicinskih tekhnologij. Obshchie polozheniya. Utverzhden i vveden v dejstvie prikazom Federal’nogo agentstva po tekhnicheskomu regulirovaniyu i metrolo-gii Rossijskoj Federacii ot 11 iyunya 2014 g. N 568-st. (In Russ). [Электронный ресурс] Режим доступа: http://docs.cntd.ru/document/1200111499
12. Nacional’nyj standart Rossijskoj Federacii. GOST R 57525-2017. Kliniko-ehkonomicheskie issledovaniya. Obshchie trebovaniya. Utverzhden i vveden v dej-stvie Prikazom Federal’nogo agentstva po tekhnicheskomu regulirovaniyu i metrologii ot 6 iyulya 2017 g. N 655-st. (In Russ). [Электронный ресурс] Режим доступа: http://docs.cntd.ru/document/1200146142
13. Osnovnye ponyatiya v ocenke medicinskih tekhnologij: metod. posobie. Pod. red. Kolbina AS, Zyryanova SK, Belousova DYu. Moscow: Izdatel’stvo OKI, 2013. (In Russ).
14. Gosudarstvennyj reestr predel’nyh otpusknyh cen (In Russ). http://grls.rosminzdrav.ru/pricelims.aspx
15. www.zakupki.gov.ru —Oficial’nyj sajt Rossijskoj Federacii dlya razmeshcheniya informacii o raz-meshchenii zakazov. 2016. (In Russ).
16. General’noe tarifnoe soglashenie OMS na 2018 g. Sankt-Peterburg. (In Russ). URL: www.spboms.ru
17. Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113—9.
18. Otchet «Ocenka pacientskih potokov. Analiz tekushchej praktiki lecheniya i al-goritma naznachenij v segmente HER2-polozhitel’nogo raka molochnoj zhelezy». Vypolneno MarConsult po zakazu ZAO «Roche-Moscow», 2015. Russ).
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205—16.
20. Federal’naya sluzhba gosudarstvennoj statistiki. Russ). Электронный ресурс: URL: http://www.gks.ru
Review
For citations:
Kolbin A.S., Kurylev A.A., Balykina Y.E., Proskurin M.A. An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2018;(4):25-32. (In Russ.) https://doi.org/10.24411/2588-0519-2018-10056
Views:
844
Email this article 